Myocarditis is necessary for the development of arrhythmogenic cardiomyopathy
Active Project Grant Awarded Last action
- Award ID
- F31HL178200
- Recipient
-
University Of Utah UEI LL8GLEVH6MG3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $188,057
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 88% complete
- Place of performance
- Salt Lake City, UT 84112, USA
Award details come from USAspending.gov.
Description
- Abstract
- Arrhythmogenic cardiomyopathy (ACM) is a devastating inherited disease that causes sudden cardiac death in young people, accounting for up to 22% of sudden cardiac deaths in adults under 35. Despite the identification of causative mutations, the mechanisms triggering ACM remain elusive, and there are no preventative therapies for individuals carrying pathogenic allele variants. This project aims to elucidate the role of early immune cell infiltration in the development of ACM using a mouse model with a mutation in the desmosomal protein desmoglein-2 (DSG2). The central hypothesis is that early myocardial immune cell populations and inflammation determine ACM phenotype severity. Aim 1 will test whether increased neonatal immune cell recruitment accelerates arrhythmias, scar formation, and death in DSG2 mice using an adeno-associated viral vector expressing a modified covid-19 spike protein. Aim 2 will investigate if neonatal treatment with gene therapy expressing the connexin-43 isoform GJA1-20K reduces immune cell burden, inflammation, arrhythmias, and death. Aim 3 will examine whether neonatal inhibition of nfκb signaling using AAV9-A20 can prevent immune cell recruitment, inflammation, arrhythmias, and scarring. This research is significant because IT explores a novel preventative treatment strategy for ACM, focusing on early immune-mediated events that precede overt cardiac dysfunction. The approach is innovative in its examination of the early stages of ACM pathophysiology and the use of gene therapies targeting different pathways involved in disease development. The expected outcomes include identifying the role of immune cell infiltration in ACM, demonstrating the efficacy of two gene therapies, and offering a new treatment paradigm focusing on early intervention to prevent disease onset in genetically susceptible individuals. If successful, this work could transform the clinical management of ACM and potentially other genetic cardiomyopathies.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $576 | |
| Amendment | $37,609 | |
| Amendment | $37,609 | |
| Amendment | $564 | |
| Amendment | $564 | |
| Amendment | $37,045 | |
| Amendment | $37,045 | |
| Amendment | $0 | |
| Amendment | $37,045 | |
| Original award | $0 |
Quick answers
Who received award F31HL178200?
F31HL178200 was awarded to University Of Utah by National Heart Lung and Blood Institute (National Institutes of Health) on June 20, 2025.
How much is award F31HL178200 worth?
$188,057 has been obligated on F31HL178200.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award